USFDAMay 28, 2026, 07:06 AM
Zenas BioPharma Submits BLA for Obexelimab in IgG4-RD
AI Summary
Zenas BioPharma announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration for obexelimab, an investigational therapy for Immunoglobulin G4-Related Disease (IgG4-RD). This submission is based on positive results from the Phase 3 INDIGO trial, where obexelimab significantly reduced the risk of IgG4-RD flare by 56% compared to placebo and met all key secondary endpoints. The company believes obexelimab could serve as a first-line therapy for long-term management of IgG4-RD, with data to be presented at the EULAR 2026 Congress. Zenas also expects to report topline results from a Phase 2 trial for Systemic Lupus Erythematosus in Q4 2026.
Key Highlights
- Zenas BioPharma submitted a Biologics License Application (BLA) to the U.S. FDA for obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD).
- The BLA is supported by positive results from the Phase 3 INDIGO registrational trial.
- Obexelimab demonstrated a highly statistically significant 56% reduction in IgG4-RD flare risk compared to placebo (HR 0.44, p=0.0005).
- The therapy met all four key secondary endpoints with high statistical significance and was generally well tolerated.
- Data from the INDIGO trial will be presented at the EULAR 2026 Congress on June 4, 2026.
- Topline results from a Phase 2 trial for Systemic Lupus Erythematosus are expected in Q4 2026.
Price Impact
More from ZBIO